Harvard Bioscience (HBIO) Payables (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Payables data on file, last reported at $5.3 million in Q1 2026.

• Payables for Q1 2026 came in at $5.3 million, up 9.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (up 9.96% YoY), and the FY2025 annual result was $3.7 million, down 23.71% from the prior year.
• Payables climbed to $5.3 million in Q1 2026 per HBIO's latest filing, from $3.7 million in the prior quarter.
• Over five years, Payables peaked at $6.8 million in Q2 2022 and troughed at $3.7 million in Q4 2025.
• A 5-year average of $5.5 million and a median of $5.6 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2023: Payables jumped 31.28% in 2022, then sank 30.75% in 2023.
• A 5-year view of Payables shows it stood at $6.4 million in 2022, then decreased by 13.85% to $5.6 million in 2023, then retreated by 13.81% to $4.8 million in 2024, then dropped by 23.71% to $3.7 million in 2025, then surged by 44.77% to $5.3 million in 2026.
• Business Quant data shows HBIO's Payables at $5.3 million in Q1 2026, $3.7 million in Q4 2025, and $5.2 million in Q3 2025.